spacer
home > ict > winter 2019 > the balanced approach to optimising clinical trial design and execution
PUBLICATIONS
International Clinical Trials

The Balanced Approach to Optimising Clinical Trial Design and Execution

According to internal Phase 2 termination analysis, as many as 17% of clinical trials fail to answer the questions their sponsors had aimed to address (1). These failed trials end up wasting significant time, money, and resources, effectively ending with a whimper instead of a bang. Moreover, such failures are especially upsetting to patient communities, who must wait longer for new treatments.

In many cases, sponsors conduct dozens of trials at once without comprehensive data-led design and planning. All too often, sponsors activate hundreds of sites for a single trial without thoroughly analysing investigator site performance data. Even when a trial results in regulatory approval, it may have been dogged by a lack of operational excellence.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gen Li PhD is founder and President of Phesi and is passionate about improving patients’ lives. Prior to founding Phesi in 2007, Gen was Head of Productivity at Pfizer in clinical development, following Pfizer’s acquisition of Pharmacia where he delivered the first implementation of clinical development productivity measurement. At Pharmacia/Pfizer, Gen significantly contributed to the Centre for Medicines Research international database for pharmaceutical R&D performance. Previously, he led the creation of the first computer-automated resource management system at Bristol-Myers Squibb. He earned his PhD in biochemistry from Beijing University, China, and an MBA from the Johnson Graduate School of Management at Cornell University, US.

Paul Chew MD is a board-certified cardiologist and internist and Chief Medical Officer at Phesi. He recently served as CMO at Silicon Valley-based Omada Health. Previously, Paul held various positions at Sanofi and Bristol- Myers Squibb, including Senior Vice President, Global Chief Medical Officer, and US R&D Head. He is currently on the Board of Trustees for the US Pharmacopoeial Convention. Paul spent 22 years at Johns Hopkins University, US, where he received his undergraduate and medical education, served his Osler medical residency, was a member of the interventional cardiology faculty, and held joint faculty appointments in radiology and cardiology.

Jonathan Peachey is Chief Operations Officer at Phesi with a background in business and IT transformation across pharma R&D for the past 25 years. Jonathan came to Phesi after serving as a Board Director at Kinapse, where he transformed the advisory and outsourcing delivery model for life sciences companies. Previously, Jonathan delivered business transformation for IBM’s EU pharma R&D consulting practice. He also led development projects at GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer. Jonathan’s demonstrated capabilities span strategy, business and IT management, performance improvement and solution design, through to implementation. He holds a first class honours degree and an Advanced Strategy diploma from Said Business School, Oxford University, UK.


spacer
Gen Li PhD
spacer
spacer
spacer
Paul Chew MD
spacer
spacer
spacer
Jonathan Peachey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Envigo launches PATHWAY an optimized safety assessment solution to enable first in human clinical trials

11 March 2019, East Millstone, N.J. – Envigo, a leading provider of non-clinical contract research services and research models, announced today the launch of PATHWAY – an integrated solution that optimizes non-clinical safety assessment programs to enable first-in-human clinical trials. PATHWAY is designed to manage the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers by integrating safety assessment study types and bioanalytical support with scientific and regulatory consulting, program design and project management.
More info >>

White Papers

Inhaler Adherence: Exploring Key Factors

Aptar Pharma

Aptar Pharma recently hosted an expert panel roundtable on “Inhaler Adherence”. This international scientific forum was held in Paris, France on November 29th 2013. The roundtable was organized to explore and exchange views on the issues which may influence inhaler adherence/ compliance with a particular focus on asthma and C.O.P.D. therapies and their corresponding inhaler devices (MDIs, DPIs).
More info >>

 
Industry Events

Bio Europe Spring 2019

25-27 March 2019, Messe Wien Exhibition and Congress Center, Vienna

BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement